Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Cryogenic Solutions Inc. (CYGS) -- Ignore unavailable to you. Want to Upgrade?

To: Graham Marshman who wrote (4021)	6/8/2000 10:00:00 PM
From: JMarcus	Read Replies (1) \| Respond to of 4028

The following shareholder update (dated May 24, 2000) appears on the company's website: cytogenix.com The SEC Saga Continues? We have so far filed five amendments to our original 10SB, but have yet to completely satisfy the SEC examiners. It begins to seem that each answer we provide provokes two new questions. We take only a little comfort in the fact that we are not alone? the SEC is badly backed up trying to respond to thousands of filings and amendments from companies of all types, most of which are dealing with technologies and structures that everyone understands. As a leading edge biotech, we have a particular challenge in presenting the specialized nature of genetics and molecular biology in language that is familiar and understandable to people whose daily focus is financial data. Knowledge of other companies? experience and our own persuades us that it is futile to try to predict how long the process will take, but the fundamentals of CytoGenix are unchanged. We continue to plow new ground, plant the seeds, and cultivate the newest technologies, confident of the long-term rewards for those who persevere. We are conducting experiments in our own laboratories and have initiated two new sponsored research programs at a local research institution. The ultimate value of the TroVec technology is in no way diminished by the current compliance challenge. It is time consuming, frustrating, aggravating, and expensive. It is also unavoidable in today?s complex regulatory environment. We appreciate the assurances, comments, and concerns of our shareholders as expressed in your calls and emails. Feel free to contact us at any time, but be assured that any updates and news of progress will be promptly posted on the website then be the subject of an appropriate press release. In the interim, we suggest that anyone wishing to trade our stock consider E-trade. E-trade will execute limit orders (most online brokers won?t) and they promptly quote the most recent transaction along with high, low and volumes.